Correspondence 0001140361-23-020659 from Elicio Therapeutics, Inc. (ELTX) (CIK 0001601485) (ELTX)
Elicio Therapeutics, Inc. (ELTX) (CIK 0001601485)
Date: April 26, 2023 · CIK: 0001601485 · Accession: 0001140361-23-020659
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-269741
Letter
Via Edgar United States Securities and Exchange Commission Division of Corporation Finance Lynn Dicker Re: Angion Biomedica Corp. Registration Statement on Form S-4 (File No. 333-269741)
Dear Mr. McNamara:
This letter is sent on behalf of Angion Biomedica Corp. (the “Company”) in connection with the above-referenced Registration Statement on Form S-4 (the “Registration Statement”) filed with the Securities and Exchange Commission (the “Commission”) by the Company pursuant to the Securities Act of 1933, as amended (the “Securities Act”). Pursuant to Rule 461 promulgated under the Securities Act, the Company hereby requests that the effective date of the Registration Statement be accelerated to 4:00 p.m., Eastern Time, on April 28, 2023, or as soon thereafter as practicable.
Please contact Anitha Anne of Cooley LLP, at (415) 693 2250, with any questions you may have concerning this request. In addition, please notify Ms. Anne when the request for acceleration has been granted.
Sincerely,
Angion Biomedica Corp.
Show Raw Text
CORRESP
1
filename1.htm
Angion Biomedica Corp.
7-57 Wells Ave.
Newton, Massachusetts 02459
April 26, 2023
Via Edgar
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn:
Jimmy McNamara
Tim Buchmiler
Christine Torney
Lynn Dicker
Re:
Angion Biomedica Corp.
Registration Statement on Form S-4 (File No. 333-269741)
Dear Mr. McNamara:
This letter is sent on behalf of Angion Biomedica Corp. (the “Company”) in connection with the above-referenced Registration Statement on Form S-4 (the “Registration Statement”) filed with the Securities
and Exchange Commission (the “Commission”) by the Company pursuant to the Securities Act of 1933, as amended (the “Securities Act”). Pursuant to Rule 461 promulgated under the Securities Act, the Company hereby requests that the
effective date of the Registration Statement be accelerated to 4:00 p.m., Eastern Time, on April 28, 2023, or as soon thereafter as practicable.
Please contact Anitha Anne of Cooley LLP, at (415) 693 2250, with any questions you may have concerning this request. In addition, please notify Ms. Anne when the request for acceleration has been granted.
Sincerely,
Angion Biomedica Corp.
By:
/s/ Jay R. Venkatesan
Name:
Jay R. Venkatesan, M.D.
Title:
President and Chief Executive Officer
cc:
Jennifer Rhodes, Angion Biomedica Corp.
Robert Connelly, Elicio Therapeutics, Inc.
Kenneth Guernsey, Cooley LLP
Brett D. White, Cooley LLP
Anitha Anne, Cooley LLP
Daniel A. Bagliebter, Mintz Levin Cohn Ferris, Glovsky & Popeo, P.C.